Skip to main content
Erschienen in: Journal of Cancer Survivorship 4/2016

11.02.2016

Predictors of attendance at specialized survivor clinics in a population-based cohort of adult survivors of childhood cancer

verfasst von: Paul C. Nathan, Mohammad Agha, Jason D. Pole, David Hodgson, Astrid Guttmann, Rinku Sutradhar, Mark L. Greenberg

Erschienen in: Journal of Cancer Survivorship | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of the present study is to determine predictors of attendance at a network of publicly funded specialized survivor clinics by a population-based cohort of adult survivors of childhood cancer.

Methods

We conducted a retrospective study linking data on eligible patients identified in a provincial pediatric cancer registry with health administrative databases to determine attendance at five specialized survivor clinics in the Canadian province of Ontario between 1999 and 2012. Eligible survivors were treated for cancer at ≤18 years between 1986 and 2005, had survived ≥5 years from their most recent pediatric cancer event, and contributed ≥1 year of follow-up after age 18 years. We assessed the impact of cancer type, treatment intensity, cumulative chemotherapy doses, radiation, socioeconomic status, distance to nearest clinic, and care from a primary care physician (PCP) on attendance using recurrent event multivariable regression.

Results

Of 7482 children and adolescents treated for cancer over the study period, 3972 were eligible for study inclusion, of which 3912 successfully linked to administrative health data. After a median of 7.8 years (range 0.2–14.0) of follow-up, 1695/3912 (43.3 %) had attended at least one adult survivor clinic visit. Significantly increased rates of attendance were associated with female gender, higher treatment intensity, radiation, higher alkylating agent exposure, higher socioeconomic status, and an annual exam by a PCP. Distance significantly impacted attendance with survivors living >50 km away less likely to attend than those living within 10 km (relative rate 0.77, p = 0.003).

Conclusion

Despite free access to survivor clinics, the majority of adult survivors of childhood cancer do not attend.

Implications for Cancer Survivors

Alternate models of care need to be developed and assessed, particularly for survivors living far from a specialized clinic and those at lower risk of developing late effects.
Literatur
1.
Zurück zum Zitat Phillips SM et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Biomarkers Prev. 2015;24(4):653–63.CrossRefPubMedPubMedCentral Phillips SM et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Biomarkers Prev. 2015;24(4):653–63.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington, D.C.: National Academies Press; 2005. Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington, D.C.: National Academies Press; 2005.
5.
Zurück zum Zitat Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24(32):5117–24.CrossRefPubMed Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24(32):5117–24.CrossRefPubMed
6.
Zurück zum Zitat Blaauwbroek R et al. Shared care by paediatric oncologists and family doctors for long-term follow-up of adult childhood cancer survivors: a pilot study. Lancet Oncol. 2008;9(3):232–8.CrossRefPubMed Blaauwbroek R et al. Shared care by paediatric oncologists and family doctors for long-term follow-up of adult childhood cancer survivors: a pilot study. Lancet Oncol. 2008;9(3):232–8.CrossRefPubMed
7.
Zurück zum Zitat Kazak AE et al. A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment. Pediatr Blood Cancer. 2012;59(1):96–9.CrossRefPubMed Kazak AE et al. A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment. Pediatr Blood Cancer. 2012;59(1):96–9.CrossRefPubMed
8.
Zurück zum Zitat Green DM et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014;61(1):53–67.CrossRefPubMed Green DM et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014;61(1):53–67.CrossRefPubMed
9.
Zurück zum Zitat Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 4.0. Monrovia, CA: Children’s Oncology Group; 2013. Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 4.0. Monrovia, CA: Children’s Oncology Group; 2013.
10.
Zurück zum Zitat Pilote L et al. Universal health insurance coverage does not eliminate inequities in access to cardiac procedures after acute myocardial infarction. Am Heart J. 2003;146(6):1030–7.CrossRefPubMed Pilote L et al. Universal health insurance coverage does not eliminate inequities in access to cardiac procedures after acute myocardial infarction. Am Heart J. 2003;146(6):1030–7.CrossRefPubMed
11.
Zurück zum Zitat Ballantyne M et al. Maternal and infant predictors of attendance at neonatal follow-up programmes. Child Care Health Dev. 2014;40(2):250–8.CrossRefPubMed Ballantyne M et al. Maternal and infant predictors of attendance at neonatal follow-up programmes. Child Care Health Dev. 2014;40(2):250–8.CrossRefPubMed
12.
Zurück zum Zitat Matheson FI et al. Development of the Canadian Marginalization Index: a new tool for the study of inequality. Can J Public Health. 2012;103(8 Suppl 2):S12–6.PubMed Matheson FI et al. Development of the Canadian Marginalization Index: a new tool for the study of inequality. Can J Public Health. 2012;103(8 Suppl 2):S12–6.PubMed
13.
14.
15.
Zurück zum Zitat Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Statistics for biology and health. New York: Springer; 2000. xiii, 350 p. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Statistics for biology and health. New York: Springer; 2000. xiii, 350 p.
16.
Zurück zum Zitat Guo Z, Gill TM, Allore HG. Modeling repeated time-to-event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons. Methods Inf Med. 2008;47(2):107–16.PubMedPubMedCentral Guo Z, Gill TM, Allore HG. Modeling repeated time-to-event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons. Methods Inf Med. 2008;47(2):107–16.PubMedPubMedCentral
17.
Zurück zum Zitat Lawless JF, Nadeau C. Some simple robust methods for the analysis of recurrent events. Technometrics. 1995;37(2):158–68.CrossRef Lawless JF, Nadeau C. Some simple robust methods for the analysis of recurrent events. Technometrics. 1995;37(2):158–68.CrossRef
18.
Zurück zum Zitat Park ER, et al. Childhood cancer survivor study participants’ perceptions and understanding of the affordable care act. J Clin Oncol. 2015;33(7):764–72. Park ER, et al. Childhood cancer survivor study participants’ perceptions and understanding of the affordable care act. J Clin Oncol. 2015;33(7):764–72.
19.
Zurück zum Zitat Oeffinger KC, et al. Models of cancer survivorship health care: moving forward. Am Soc Clin Oncol Educ Book. 2014; 205–13. Oeffinger KC, et al. Models of cancer survivorship health care: moving forward. Am Soc Clin Oncol Educ Book. 2014; 205–13.
20.
21.
Zurück zum Zitat Zheng DJ, et al. Patterns and predictors of survivorship clinic attendance in a population-based sample of pediatric and young adult childhood cancer survivors. J Cancer Surviv. 2015. doi:10.1007/s11764-015-0493-4. Zheng DJ, et al. Patterns and predictors of survivorship clinic attendance in a population-based sample of pediatric and young adult childhood cancer survivors. J Cancer Surviv. 2015. doi:10.​1007/​s11764-015-0493-4.
22.
Zurück zum Zitat Nathan PC, et al. Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. J Cancer Surviv. 2013;7(3):275–82. Nathan PC, et al. Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. J Cancer Surviv. 2013;7(3):275–82.
23.
Zurück zum Zitat Suh E et al. General internists’ preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey. Ann Intern Med. 2014;160(1):11–7.CrossRefPubMedPubMedCentral Suh E et al. General internists’ preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey. Ann Intern Med. 2014;160(1):11–7.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Nathan PC et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2008;26(27):4401–9.CrossRefPubMedPubMedCentral Nathan PC et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2008;26(27):4401–9.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Eshelman-Kent D et al. Cancer survivorship practices, services, and delivery: a report from the Children’s Oncology Group (COG) nursing discipline, adolescent/young adult, and late effects committees. J Cancer Surviv. 2011;5(4):345–57.CrossRefPubMedPubMedCentral Eshelman-Kent D et al. Cancer survivorship practices, services, and delivery: a report from the Children’s Oncology Group (COG) nursing discipline, adolescent/young adult, and late effects committees. J Cancer Surviv. 2011;5(4):345–57.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Ristovski-Slijepcevic S et al. A cross-Canada survey of clinical programs for the care of survivors of cancer in childhood and adolescence. Pediatr Child Health. 2009;14(6):375–8. Ristovski-Slijepcevic S et al. A cross-Canada survey of clinical programs for the care of survivors of cancer in childhood and adolescence. Pediatr Child Health. 2009;14(6):375–8.
28.
Zurück zum Zitat Blaauwbroek R et al. Family doctor-driven follow-up for adult childhood cancer survivors supported by a web-based survivor care plan. J Cancer Surviv. 2012;6(2):163–71.CrossRefPubMed Blaauwbroek R et al. Family doctor-driven follow-up for adult childhood cancer survivors supported by a web-based survivor care plan. J Cancer Surviv. 2012;6(2):163–71.CrossRefPubMed
29.
Zurück zum Zitat Bertakis KD et al. Gender differences in the utilization of health care services. J Fam Pract. 2000;49(2):147–52.PubMed Bertakis KD et al. Gender differences in the utilization of health care services. J Fam Pract. 2000;49(2):147–52.PubMed
30.
Zurück zum Zitat Kadan-Lottick NS et al. Childhood cancer survivors’ knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA. 2002;287(14):1832–9.CrossRefPubMed Kadan-Lottick NS et al. Childhood cancer survivors’ knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA. 2002;287(14):1832–9.CrossRefPubMed
31.
Zurück zum Zitat Cherven B et al. Knowledge and risk perception of late effects among childhood cancer survivors and parents before and after visiting a childhood cancer survivor clinic. J Pediatr Oncol Nurs. 2014;31(6):339–49.CrossRefPubMed Cherven B et al. Knowledge and risk perception of late effects among childhood cancer survivors and parents before and after visiting a childhood cancer survivor clinic. J Pediatr Oncol Nurs. 2014;31(6):339–49.CrossRefPubMed
32.
Zurück zum Zitat Stricker CT, O’Brien M. Implementing the commission on cancer standards for survivorship care plans. Clin J Oncol Nurs. 2014;18(Suppl):15–22.CrossRefPubMed Stricker CT, O’Brien M. Implementing the commission on cancer standards for survivorship care plans. Clin J Oncol Nurs. 2014;18(Suppl):15–22.CrossRefPubMed
33.
Zurück zum Zitat Hudson MM et al. Increasing cardiomyopathy screening in at-risk adult survivors of pediatric malignancies: a randomized controlled trial. J Clin Oncol. 2014;32(35):3974–81.CrossRefPubMedPubMedCentral Hudson MM et al. Increasing cardiomyopathy screening in at-risk adult survivors of pediatric malignancies: a randomized controlled trial. J Clin Oncol. 2014;32(35):3974–81.CrossRefPubMedPubMedCentral
Metadaten
Titel
Predictors of attendance at specialized survivor clinics in a population-based cohort of adult survivors of childhood cancer
verfasst von
Paul C. Nathan
Mohammad Agha
Jason D. Pole
David Hodgson
Astrid Guttmann
Rinku Sutradhar
Mark L. Greenberg
Publikationsdatum
11.02.2016
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 4/2016
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-016-0522-y

Weitere Artikel der Ausgabe 4/2016

Journal of Cancer Survivorship 4/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.